Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group
Javier G. Blanco,Can Lan Sun,Wendy Landier,Lu Chen,Diego Esparza-Duran,Wendy M. Leisenring,Allison Mays,Debra L. Friedman,Jill P. Ginsberg,Melissa M. Hudson,Joseph P. Neglia,Kevin C. Oeffinger,A. Kim Ritchey,Doojduen Villaluna,Mary V. Relling,Smita Bhatia +15 more
TLDR
Increased anthracycline-related cardiomyopathy risk at doses as low as 101 to 150 mg/m(2) is demonstrated, such that there seems to be no safe dose for patients homozygous for the CBR3 V244M G allele.Citations
More filters
Journal ArticleDOI
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Jyoti D. Patel,Lada Krilov,Sylvia Adams,Carol Aghajanian,Ethan Basch,Marcia S. Brose,William L. Carroll,Marcos de Lima,Mark R. Gilbert,Mark G. Kris,John L. Marshall,Gregory A. Masters,Steven J. O'Day,Blase N. Polite,Gary K. Schwartz,Sunil Sharma,Ian M. Thompson,Nicholas J. Vogelzang,Bruce J. Roth +18 more
TL;DR: Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology represents the invaluable contributions of thousands of patients who participate in clinical trials and the scientists who conduct basic and clinical research.
Journal ArticleDOI
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.
Biykem Bozkurt,Monica Colvin,Jennifer L. Cook,Leslie T. Cooper,Anita Deswal,Gregg C. Fonarow,Gary S. Francis,Daniel J. Lenihan,Eldrin F. Lewis,Dennis M. McNamara,Elfriede Pahl,Ramachandran S. Vasan,Kumudha Ramasubbu,Kismet Rasmusson,Jeffrey A. Towbin,Clyde W. Yancy +15 more
TL;DR: The intent of this American Heart Association (AHA) scientific statement is to summarize the current understanding of dilated cardiomyopathies, with special emphasis on recent developments in diagnostic approaches and therapies for specific cardiologyopathies.
Journal ArticleDOI
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Saro H. Armenian,Melissa M. Hudson,Renée L. Mulder,Ming-Hui Chen,Louis S. Constine,Mary Dwyer,Paul C. Nathan,Wim J. E. Tissing,Sadhna M. Shankar,Elske Sieswerda,Rod Skinner,Julia Steinberger,Elvira C. van Dalen,Helena J.H. van der Pal,W. Hamish B. Wallace,Gill Levitt,Leontien C. M. Kremer +16 more
TL;DR: The results of an international collaboration to harmonise existing cardiomyopathy surveillance recommendations using an evidence-based approach that relied on standardised definitions for outcomes of interest and transparent presentation of the quality of the evidence are reported.
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,D. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.
Robert L. Page,Cindy L. O'Bryant,Davy Cheng,Tristan J. Dow,Bonnie Ky,C. Michael Stein,Anne P. Spencer,Robin J. Trupp,JoAnn Lindenfeld +8 more
TL;DR: This scientific statement is designed to serve as a comprehensive and accessible source of drugs that may cause or exacerbate heart failure to assist healthcare providers in improving the quality of care for these patients.
References
More filters
Journal ArticleDOI
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Journal ArticleDOI
A structural approach to selection bias.
TL;DR: This work argues that the causal structure underlying the bias in each example is essentially the same: conditioning on a common effect of 2 variables, one of which is either exposure or a cause of exposure and the other is either the outcome or acause of the outcome.
Journal ArticleDOI
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Holcombe E. Grier,Mark Krailo,Nancy J. Tarbell,Michael P. Link,Chris Fryer,Douglas J. Pritchard,Mark C. Gebhardt,Paul S. Dickman,Elizabeth J. Perlman,Paul A. Meyers,Sarah S. Donaldson,Sheila Moore,Aaron R. Rausen,Teresa J. Vietti,James S. Miser +14 more
TL;DR: The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcomeFor patients with nonmetastatic Ewing's Sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.
Journal ArticleDOI
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.
Daniel A. Mulrooney,Mark W. Yeazel,Toana Kawashima,Ann C. Mertens,Pauline Mitby,Marilyn Stovall,Sarah S. Donaldson,Daniel M. Green,Charles A. Sklar,Leslie L. Robison,Wendy M. Leisenring +10 more
TL;DR: Survivors of childhood and adolescent cancer are at substantial risk for cardiovascular disease, and healthcare professionals must be aware of these risks when caring for this growing population.
Journal ArticleDOI
Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
Steven E. Lipshultz,Stuart R. Lipsitz,Stephen E. Sallan,Virginia M. Dalton,Suzanne M. Mone,Richard D. Gelber,Steven D. Colan +6 more
TL;DR: Cardiac abnormalities were persistent and progressive after doxorubicin therapy, and inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced cardiac output and restrictive cardiomyopathy.
Related Papers (5)
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Leszek Wojnowski,Bettina Kulle,Markus D. Schirmer,Gregor Schlüter,Albrecht Schmidt,Albert Rosenberger,Stefan Vonhof,Heike Bickeböller,Mohammad R. Toliat,Eun-Kyung Suk,Mladen V. Tzvetkov,Anke Kruger,Silvia Seifert,Marita Kloess,Heidi Hahn,Markus Loeffler,Peter Nürnberg,Michael Pfreundschuh,Lorenz Trümper,Jürgen Brockmöller,Gerd Hasenfuss +20 more